Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636959 | 1.00 | HCRTR1 (0.37) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3055587 | 0.98 | HCRTR1 (0.37) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3639702 | 0.98 | HCRTR1 (0.37) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3641449 | 0.92 | HCRTR1 (0.37) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3053921 | 0.92 | HCRTR1 (0.37) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3053184 | 0.91 | LMNA (0.40) | HCRTR1HCRTR2CDK2 | |
| SCHEMBL3640687 | 0.91 | GRM5 (0.38) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3638225 | 0.91 | LMNA (0.40) | HCRTR1HCRTR2CDK2 | |
| SCHEMBL3047468 | 0.91 | GRM5 (0.38) | HCRTR1HCRTR2CCNA2CDK2CCNA1 | |
| SCHEMBL3635490 | 0.89 | CCKAR (0.36) | CCNA2CDK2CCNA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | claimed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| CN-101711247-A | 2-cyclopropyl-thiazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-05-19 | — | — | CN | claimed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| CN-101711247-A | 2-cyclopropyl-thiazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-05-19 | — | — | CN | disclosed |
| EP-2155739-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885CCNA2 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.